<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35871544</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>23</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1750-3639</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Brain pathology (Zurich, Switzerland)</Title><ISOAbbreviation>Brain Pathol</ISOAbbreviation></Journal><ArticleTitle>Atypical TDP-43 protein expression in an ALS pedigree carrying a p.Y374X truncation mutation in TARDBP.</ArticleTitle><Pagination><StartPage>e13104</StartPage><MedlinePgn>e13104</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e13104</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1111/bpa.13104</ELocationID><Abstract><AbstractText>We describe an autosomal dominant, multi-generational, amyotrophic lateral sclerosis (ALS) pedigree in which disease co-segregates with a heterozygous p.Y374X nonsense mutation within TDP-43. Mislocalization of TDP-43 and formation of insoluble TDP-43-positive neuronal cytoplasmic inclusions is the hallmark pathology in &gt;95% of ALS patients. Neuropathological examination of the single case for which CNS tissue was available indicated typical TDP-43 pathology within lower motor neurons, but classical TDP-43-positive inclusions were absent from motor cortex. The mutated allele is transcribed and translated in patient fibroblasts and motor cortex tissue, but overall TDP-43 protein expression is reduced compared to wild-type controls. Despite absence of TDP-43-positive inclusions we confirmed deficient TDP-43 splicing function within motor cortex tissue. Furthermore, urea fractionation and mass spectrometry of motor cortex tissue carrying the mutation revealed atypical TDP-43 protein species but not typical C-terminal fragments. We conclude that the p.Y374X mutation underpins a monogenic, fully penetrant form of ALS. Reduced expression of TDP-43 combined with atypical TDP-43 protein species and absent C-terminal fragments extends the molecular phenotypes associated with TDP-43 mutations and with ALS more broadly. Future work will need to include the findings from this pedigree in dissecting the mechanisms of TDP-43-mediated toxicity.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors. Brain Pathology published by John Wiley &amp; Sons Ltd on behalf of International Society of Neuropathology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cooper-Knock</LastName><ForeName>Johnathan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-0873-8689</Identifier><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Julian</LastName><ForeName>Thomas H</ForeName><Initials>TH</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feneberg</LastName><ForeName>Emily</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-5905-3826</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology Department, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Highley</LastName><ForeName>J Robin</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sidra</LastName><ForeName>Maurice</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turner</LastName><ForeName>Martin R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Talbot</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ansorge</LastName><ForeName>Olaf</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Academic Unit of Neuropathology, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allen</LastName><ForeName>Scott P</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moll</LastName><ForeName>Tobias</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shelkovnikova</LastName><ForeName>Tatyana</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castelli</LastName><ForeName>Lydia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hautbergue</LastName><ForeName>Guillaume M</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hewitt</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amarin UK Limited, Amarin Corporation, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kirby</LastName><ForeName>Janine</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wharton</LastName><ForeName>Stephen B</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mead</LastName><ForeName>Richard J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Pamela J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>ALLEN/OCT15/956-799</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>BB/S005277/1</GrantID><Acronym>BB_</Acronym><Agency>Biotechnology and Biological Sciences Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>972-797</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>TURNER/OCT18/989-797</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>216596/Z/19/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>TURNER/OCT15/972-797</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>956-799</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>974-797</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>SHELKOVNIKOVA/OCT17/968-799</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/R024162/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Brain Pathol</MedlineTA><NlmUniqueID>9216781</NlmUniqueID><ISSNLinking>1015-6305</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C531617">Amyotrophic lateral sclerosis 1</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010375" MajorTopicYN="N">Pedigree</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">TDP-43</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">genetics</Keyword><Keyword MajorTopicYN="N">neuropathology</Keyword><Keyword MajorTopicYN="N">protein aggregation</Keyword></KeywordList><CoiStatement>Emily Feneberg, Kevin Talbot, Martin R. Turner, and Olaf Ansorge have a patent filed for the TDP&#x2010;43 sequences described in this work (Patent application no. 2004863.3). Other authors delare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>10</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>24</Day><Hour>21</Hour><Minute>22</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35871544</ArticleId><ArticleId IdType="pmc">PMC9836368</ArticleId><ArticleId IdType="doi">10.1111/bpa.13104</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>McDermott CJ, Shaw PJ. Diagnosis and management of motor neurone disease. BMJ. 2008;336:658&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2270983</ArticleId><ArticleId IdType="pubmed">18356234</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Chi&#xf2; A, Traynor BJ. State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci. 2014;17:17&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4544832</ArticleId><ArticleId IdType="pubmed">24369373</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, et al. Ubiquitinated TDP&#x2010;43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B, et al. TDP&#x2010;43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science. 2008;319:1668&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7116650</ArticleId><ArticleId IdType="pubmed">18309045</ArticleId></ArticleIdList></Reference><Reference><Citation>Hergesheimer RC, Chami AA, de Assis DR, Vourc'h P, Andres CR, Corcia P, et al. The debated toxic role of aggregated TDP&#x2010;43 in amyotrophic lateral sclerosis: a resolution in sight? Brain. 2019;142:1176&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6487324</ArticleId><ArticleId IdType="pubmed">30938443</ArticleId></ArticleIdList></Reference><Reference><Citation>Daoud H, Valdmanis PN, Kabashi E, Dion P, Dupr&#xe9; N, Camu W, et al. Contribution of TARDBP mutations to sporadic amyotrophic lateral sclerosis. J Med Genet. 2009;46:112&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">18931000</ArticleId></ArticleIdList></Reference><Reference><Citation>King A, Troakes C, Smith B, Nolan M, Curran O, Vance C, et al. ALS&#x2010;FUS pathology revisited: singleton FUS mutations and an unusual case with both a FUS and TARDBP mutation. Acta Neuropathol Commun. 2015;3:62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4600255</ArticleId><ArticleId IdType="pubmed">26452761</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang C&#x2010;H, Grauffel C, Wu L&#x2010;S, Kuo P&#x2010;H, Doudeva LG, Lim C, et al. Structural analysis of disease&#x2010;related TDP&#x2010;43 D169G mutation: linking enhanced stability and caspase cleavage efficiency to protein accumulation. Sci Rep. 2016;6:21581.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4756693</ArticleId><ArticleId IdType="pubmed">26883171</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown A&#x2010;L, Wilkins OG, Keuss MJ, Hill SE, Zanovello M, Lee WC, et al. TDP&#x2010;43 loss and ALS&#x2010;risk SNPs drive mis&#x2010;splicing and depletion of UNC13A. Nature. 2022;603:131&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8891020</ArticleId><ArticleId IdType="pubmed">35197628</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma XR, Prudencio M, Koike Y, Vatsavayai SC, Kim G, Harbinski F, et al. TDP&#x2010;43 represses cryptic exon inclusion in the FTD&#x2013;ALS gene UNC13A . Nature. 2022;603:124&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8891019</ArticleId><ArticleId IdType="pubmed">35197626</ArticleId></ArticleIdList></Reference><Reference><Citation>van Es MA, Veldink JH, Saris CGJ, Blauw HM, van Vught PWJ, Birve A, et al. Genome&#x2010;wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. Nat Genet. 2009;41:1083&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">19734901</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Mora G, Restagno G, Brunetti M, Ossola I, Barberis M, et al. UNC13A influences survival in Italian amyotrophic lateral sclerosis patients: a population&#x2010;based study. Neurobiol Aging. 2013;34:357.e1&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3483408</ArticleId><ArticleId IdType="pubmed">22921269</ArticleId></ArticleIdList></Reference><Reference><Citation>Klim JR, Williams LA, Limone F, Juan IGS, Davis&#x2010;Dusenbery BN, Mordes DA, et al. ALS&#x2010;implicated protein TDP&#x2010;43 sustains levels of STMN2, a mediator of motor neuron growth and repair. Nat Neurosci. 2019;22:167&#x2013;79. 10.1038/s41593-018-0300-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0300-4</ArticleId><ArticleId IdType="pmc">PMC7153761</ArticleId><ArticleId IdType="pubmed">30643292</ArticleId></ArticleIdList></Reference><Reference><Citation>Theunissen F, Anderton RS, Mastaglia FL, Flynn LL, Winter SJ, James I, et al. Novel STMN2 variant linked to amyotrophic lateral sclerosis risk and clinical phenotype. Front Aging Neurosci. 2021;13:658226.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8033025</ArticleId><ArticleId IdType="pubmed">33841129</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirby J, Goodall EF, Smith W, Highley JR, Masanzu R, Hartley JA, et al. Broad clinical phenotypes associated with TAR&#x2010;DNA binding protein (TARDBP) mutations in amyotrophic lateral sclerosis. Neurogenetics. 2010;11:217&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">19760257</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper&#x2010;Knock J, Robins H, Niedermoser I, Wyles M, Heath PR, Higginbottom A, et al. Targeted genetic screen in amyotrophic lateral sclerosis reveals novel genetic variants with synergistic effect on clinical phenotype. Front Mol Neurosci. 2017;10:370.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5684183</ArticleId><ArticleId IdType="pubmed">29170628</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuji H, Nonaka T, Yamashita M, Masuda&#x2010;Suzukake M, Kametani F, Akiyama H, et al. Epitope mapping of antibodies against TDP&#x2010;43 and detection of protease&#x2010;resistant fragments of pathological TDP&#x2010;43 in amyotrophic lateral sclerosis and frontotemporal lobar degeneration. Biochem Biophys Res Commun. 2012;417:116&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">22133678</ArticleId></ArticleIdList></Reference><Reference><Citation>Budini M, Romano V, Quadri Z, Buratti E, Baralle FE. TDP&#x2010;43 loss of cellular function through aggregation requires additional structural determinants beyond its C&#x2010;terminal Q/N prion&#x2010;like domain. Hum Mol Genet. 2015;24:9&#x2013;20. 10.1093/hmg/ddu415</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddu415</ArticleId><ArticleId IdType="pmc">PMC4262490</ArticleId><ArticleId IdType="pubmed">25122661</ArticleId></ArticleIdList></Reference><Reference><Citation>Feneberg E, Charles PD, Finelli MJ, Scott C, Kessler BM, Fischer R, et al. Detection and quantification of novel C&#x2010;terminal TDP&#x2010;43 fragments in ALS&#x2010;TDP. Brain Pathol. 2020;31:e12923.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8412074</ArticleId><ArticleId IdType="pubmed">33300249</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepheard SR, Parker MD, Cooper&#x2010;Knock J, Verber NS, Tuddenham L, Heath P, et al. Value of systematic genetic screening of patients with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2021;92:510&#x2013;8. 10.1136/jnnp-2020-325014</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2020-325014</ArticleId><ArticleId IdType="pmc">PMC8053339</ArticleId><ArticleId IdType="pubmed">33589474</ArticleId></ArticleIdList></Reference><Reference><Citation>Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alf&#xf6;ldi J, Wang Q, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020;581:434&#x2013;43. 10.1038/s41586-020-2308-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2308-7</ArticleId><ArticleId IdType="pmc">PMC7334197</ArticleId><ArticleId IdType="pubmed">32461654</ArticleId></ArticleIdList></Reference><Reference><Citation>Rentzsch P, Witten D, Cooper GM, Shendure J, Kircher M. CADD: predicting the deleteriousness of variants throughout the human genome. Nucleic Acids Res. 2019;47:D886&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6323892</ArticleId><ArticleId IdType="pubmed">30371827</ArticleId></ArticleIdList></Reference><Reference><Citation>Landrum MJ, Lee JM, Benson M, Brown GR, Chao C, Chitipiralla S, et al. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 2018;46:D1062&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5753237</ArticleId><ArticleId IdType="pubmed">29165669</ArticleId></ArticleIdList></Reference><Reference><Citation>Al&#x2010;Sarraj S, King A, Troakes C, Smith B, Maekawa S, Bodi I, et al. p62 positive, TDP&#x2010;43 negative, neuronal cytoplasmic and intranuclear inclusions in the cerebellum and hippocampus define the pathology of C9orf72&#x2010;linked FTLD and MND/ALS. Acta Neuropathol. 2011;122:691&#x2013;702.</Citation><ArticleIdList><ArticleId IdType="pubmed">22101323</ArticleId></ArticleIdList></Reference><Reference><Citation>Igaz LM, Kwong LK, Chen&#x2010;Plotkin A, Winton MJ, Unger TL, Xu Y, et al. Expression of TDP&#x2010;43 C&#x2010;terminal fragments in vitro recapitulates pathological features of TDP&#x2010;43 proteinopathies. J Biol Chem. 2009;284:8516&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2659210</ArticleId><ArticleId IdType="pubmed">19164285</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IRA, Bigio EH, Ince PG, Geser F, Neumann M, Cairns NJ, et al. Pathological TDP&#x2010;43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol. 2007;61:427&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">17469116</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiga A, Ishihara T, Miyashita A, Kuwabara M, Kato T, Watanabe N, et al. Alteration of POLDIP3 splicing associated with loss of function of TDP&#x2010;43 in tissues affected with ALS. PLoS One. 2012;7:e43120. 10.1371/journal.pone.0043120</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0043120</ArticleId><ArticleId IdType="pmc">PMC3416794</ArticleId><ArticleId IdType="pubmed">22900096</ArticleId></ArticleIdList></Reference><Reference><Citation>Broeck LV, Callaerts P, Dermaut B. TDP&#x2010;43&#x2010;mediated neurodegeneration: towards a loss&#x2010;of&#x2010;function hypothesis? Trends Mol Med. 2014;20:66&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">24355761</ArticleId></ArticleIdList></Reference><Reference><Citation>White MA, Kim E, Duffy A, Adalbert R, Phillips BU, Peters OM, et al. TDP&#x2010;43 gains function due to perturbed autoregulation in a Tardbp knock&#x2010;in mouse model of ALS&#x2010;FTD. Nat Neurosci. 2018;21:552&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5884423</ArticleId><ArticleId IdType="pubmed">29556029</ArticleId></ArticleIdList></Reference><Reference><Citation>Laferri&#xe8;re F, Maniecka Z, P&#xe9;rez&#x2010;Berlanga M, Hruska&#x2010;Plochan M, Gilhespy L, Hock E&#x2010;M, et al. TDP&#x2010;43 extracted from frontotemporal lobar degeneration subject brains displays distinct aggregate assemblies and neurotoxic effects reflecting disease progression rates. Nat Neurosci. 2019;22:65&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">30559480</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuji H, Arai T, Kametani F, Nonaka T, Yamashita M, Suzukake M, et al. Molecular analysis and biochemical classification of TDP&#x2010;43 proteinopathy. Brain. 2012;135:3380&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">23035040</ArticleId></ArticleIdList></Reference><Reference><Citation>Geser F, Brandmeir NJ, Kwong LK, Martinez&#x2010;Lage M, Elman L, McCluskey L, et al. Evidence of multisystem disorder in whole&#x2010;brain map of pathological TDP&#x2010;43 in amyotrophic lateral sclerosis. Arch Neurol. 2008;65:636&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">18474740</ArticleId></ArticleIdList></Reference><Reference><Citation>Vatsavayai SC, Yoon SJ, Gardner RC, Gendron TF, Vargas JNS, Trujillo A, et al. Timing and significance of pathological features in C9orf72 expansion&#x2010;associated frontotemporal dementia. Brain. 2016;139:3202&#x2013;16. 10.1093/brain/aww250</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww250</ArticleId><ArticleId IdType="pmc">PMC5790143</ArticleId><ArticleId IdType="pubmed">27797809</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa M, Arai T, Nonaka T, Kametani F, Yoshida M, Hashizume Y, et al. Phosphorylated TDP&#x2010;43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann Neurol. 2008;64:60&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2674108</ArticleId><ArticleId IdType="pubmed">18546284</ArticleId></ArticleIdList></Reference><Reference><Citation>Inukai Y, Nonaka T, Arai T, Yoshida M, Hashizume Y, Beach TG, et al. Abnormal phosphorylation of Ser409/410 of TDP&#x2010;43 in FTLD&#x2010;U and ALS. FEBS Lett. 2008;582:2899&#x2013;904.</Citation><ArticleIdList><ArticleId IdType="pubmed">18656473</ArticleId></ArticleIdList></Reference><Reference><Citation>Winton MJ, Igaz LM, Wong MM, Kwong LK, Trojanowski JQ, Lee VM&#x2010;Y. Disturbance of nuclear and cytoplasmic TAR DNA&#x2010;binding protein (TDP&#x2010;43) induces disease&#x2010;like redistribution, sequestration, and aggregate formation. J Biol Chem. 2008;283:13302&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2442318</ArticleId><ArticleId IdType="pubmed">18305110</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>